Introduction
============

Advancement in the knowledge surrounding the physiology of endogenous glucoregulatory peptide hormones, namely glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), has led to a rapid expansion in the availability of agents utilizing the incretin system for the treatment of type 2 diabetes mellitus (T2DM). Dipeptidyl peptidase-4 (DPP-4) inhibitors are one such class of agents that provide clinicians with a novel mechanism of action to utilize, often in combination with other therapies, for the treatment of T2DM. In fact, current clinical recommendations and guidelines advocate for the use of combination therapy approaches taking advantage of different, yet complementary, mechanisms of action to achieve glycemic goals.[@b1-dmso-7-277],[@b2-dmso-7-277] While alogliptin has been studied in a variety of combination studies including, but not limited to, as add-on to glyburide[@b3-dmso-7-277] and insulin,[@b4-dmso-7-277] this article will focus on clinical data pertaining to alogliptin used as monotherapy and as combination therapy with metformin and pioglitazone. Alogliptin is commercially available in fixed-dose combination with metformin (Kazano™; Takeda Pharmaceutical Company, Osaka, Japan) and pioglitazone (Oseni™; Takeda Pharmaceutical Company). In light of these available fixed-dose combination products, the clinical efficacy and safety data of alogliptin combination therapy will be highlighted and discussed.

Materials and methods
=====================

A MEDLINE^®^ search (1966--February 2014) was conducted with the keywords "alogliptin", "metformin", "pioglitazone", "Nesina", "Oseni", "Kazano", "incretin", and "DPP-4 inhibitor" for published clinical trials and pertinent review articles published in English. References of identified articles were searched for additional relevant sources. Articles relevant to the safety, efficacy, and pharmacology of alogliptin combinations were also identified from the references cited in works obtained from ClinicalTrials.gov and MEDLINE search results.

Pharmacology
============

The "incretin effect" is noted to be responsible for approximately 60% of postprandial insulin response, and results from peptide hormones released by the intestine in response to oral intake of nutrients.[@b5-dmso-7-277] Two incretin hormones are primarily associated with this effect. GLP-1 is produced by intestinal L-cells, and, in addition to stimulating insulin secretion in pancreatic β-cells, suppresses glucose-dependent glucagon secretion, induces satiety, and slows gastric emptying.[@b6-dmso-7-277] GIP, produced by duodenal cells, also stimulates insulin secretion but does not suppress glucagon release.[@b7-dmso-7-277]--[@b10-dmso-7-277] Both GIP and GLP-1 are metabolized by the DPP-4 enzyme. DPP-4 is a 110 kDa transmembrane aminopeptidase that cleaves N-terminal dipeptides from proteins containing proline or alanine in the second position (Xaa-Pro- or Xaa-Ala-).[@b11-dmso-7-277] DPP-4 is expressed in many different tissues, is known to be present and active in plasma when its active domain is cleaved from membrane-bound domains, and is also known as the cluster of differentiation (CD)-26 antigen when expressed in lymphocytes.[@b11-dmso-7-277] Alogliptin is a pyrimidine in structure and reversibly binds at the active catalytic site on the DPP-4 enzyme.[@b12-dmso-7-277]

As a DPP-4 inhibitor, alogliptin reduces glycosylated hemoglobin (A1c) and postprandial plasma glucose (PPG) levels by slowing the degradation of GLP-1 and GIP, in turn increasing plasma concentrations of the active peptides.[@b8-dmso-7-277],[@b11-dmso-7-277],[@b13-dmso-7-277] Because the glucose-lowering effects of DPP-4 inhibitors are dependent on the presence of dietary glucose, alogliptin itself presents a relatively low risk for hypoglycemia relative to insulin secretagogues and other antihyperglycemic agents.[@b11-dmso-7-277]

Alogliptin ([Figure 1](#f1-dmso-7-277){ref-type="fig"}) is highly selective for the DPP-4 enzyme: half-maximal inhibitory concentrations (EC~50~) for the structurally similar enzymes DPP-2, DPP-8, DPP-9, and fibroblast activation protein are \>10,000× the EC~50~ for DPP-4.[@b8-dmso-7-277],[@b11-dmso-7-277],[@b14-dmso-7-277] Alogliptin preferentially inhibits DPP-4 over DPP-8 or DPP-9 by a factor of more than 14,000.[@b12-dmso-7-277] Inhibition of related proteases, particularly DPP-8 and DPP-9, has been associated with toxicity in animal models and reduced activation of human T-cells, making selectivity a desirable attribute and a likely contributor to the generally sound safety profile associated with alogliptin monotherapy.[@b8-dmso-7-277],[@b15-dmso-7-277]

Pharmacokinetics and pharmacodynamics
=====================================

In a trial of alogliptin in 54 adult T2DM patients, 25 mg once-daily dosing of alogliptin produced a time following administration to maximum plasma concentration (T~max~) of 1--2 hours, half-life (t~1/2~) of approximately 21 hours (standard deviation \[SD\] =8.8), and an approximately linear relationship between dose and area under the curve (AUC) throughout and well beyond the therapeutic range.[@b8-dmso-7-277],[@b12-dmso-7-277] A trial of single increasing doses in healthy male subjects showed similar pharmacokinetic parameters for therapeutic doses (25 mg), with no dose-limiting toxicity with single doses of up to 800 mg.[@b13-dmso-7-277] Alogliptin has a reported EC~50~ of 6.6 ng/mL, with peak inhibition ranging from 94% to 99%, and inhibition at 24 hours in the range of 81% to 97% after 14 days at the approved once-daily 25 mg dose.[@b6-dmso-7-277] Once-daily administration of alogliptin 25 mg increases the AUC of active GLP-1 by approximately two- to threefold.

Alogliptin is primarily excreted renally, with 60%--71% excreted unchanged in the urine within 72 hours of dosing. Renal clearance after 14 days of 25 mg/day dosing was approximately 175--200 mL/minute, suggesting some level of active renal secretion.[@b8-dmso-7-277],[@b13-dmso-7-277],[@b16-dmso-7-277] A single-dose pharmacokinetic evaluation of alogliptin in patients with moderate hepatic impairment (Child--Pugh score of 7--9) showed the maximum concentration (C~max~) and AUC of alogliptin decreased by approximately 10%, while the T~max~ increased by 2.5 hours.[@b17-dmso-7-277] Inactive metabolites form a minor portion of the elimination pathway, and are also excreted renally.[@b16-dmso-7-277]

In a study by Karim and colleagues, patients were stratified by age, race, and sex and administered alogliptin 25 mg on day 1 and days 4--8.[@b18-dmso-7-277] Clinically significant changes in alogliptin exposure were not seen between groups, although exposure was increased in the elderly when compared with the young, in white people compared with black people, and in female subjects relative to male subjects.[@b18-dmso-7-277] However, age, race, and sex did not appear to alter DPP-4 inhibition, indicating that dosage adjustments are not needed based on these patient characteristics.[@b18-dmso-7-277]

Alogliptin absorption is substantially unchanged when administered with food, with no change in the AUC~0--∞~ and a clinically insignificant reduction in C~max~.[@b19-dmso-7-277] Co-administration of pioglitazone and alogliptin results in a slight decrease in alogliptin T~max~ with an approximately 10% increase in C~max~ and AUC.[@b16-dmso-7-277] Trough concentrations of alogliptin were also increased by approximately 14%. However, these interactions were regarded as clinically nonsignificant and 90% confidence intervals were within the bioequivalence range of 0.8--1.25. A two-phase crossover study conducted by Karim et al[@b19-dmso-7-277] found that alogliptin did not affect metformin C~max~ and had a clinically insignificant effect on metformin AUC. Metformin had no effect on alogliptin pharmacokinetic parameters.[@b19-dmso-7-277]

Efficacy: clinical trial data
=============================

As noted previously, while alogliptin has been studied in combination and as add-on to a variety of background therapies, clinical trial data with alogliptin in combination with metformin and pioglitazone are highlighted herein. As a basis of comparison, a brief discussion of alogliptin monotherapy is first presented. [Table 1](#t1-dmso-7-277){ref-type="table"} provides a summary of select efficacy data from the clinical studies described in the following sections.[@b20-dmso-7-277]--[@b26-dmso-7-277]

Alogliptin monotherapy in drug-naïve patients
---------------------------------------------

Prior to discussing the clinical efficacy of alogliptin as a component of combination therapy, it is useful to examine its effectiveness as monotherapy in drug-naïve individuals. Accordingly, two studies with alogliptin used as monotherapy in drug-naïve patients are briefly described here.

The first study was a double-blind, placebo-controlled, multicenter trial enrolling 329 participants with T2DM.[@b27-dmso-7-277] This trial compared 26 weeks of treatment with alogliptin 12.5 mg daily (n=133), alogliptin 25 mg daily (n=131), or placebo (n=65). Enrolled participants had a baseline A1c of 7%--10% despite lifestyle management for ≥1 month, and a baseline body mass index of 23--45 kg/m^2^. At 26 weeks, participants experienced a mean decrease in A1c from baseline of −0.56, −0.59, and −0.02% in the alogliptin 12.5 mg, alogliptin 25.0 mg, and placebo groups, respectively (*P*\<0.001 for both alogliptin groups when compared with placebo). These mean changes in A1c additionally led to a larger percent of alogliptin-treated participants achieving a goal A1c of ≤7.0% (47.4%, 44.3%, and 23.4% in the three treatment groups, respectively). Participants receiving alogliptin likewise achieved a statistically significant reduction in fasting plasma glucose (FPG) values from baseline when compared with those receiving placebo (*P*\<0.001 for both alogliptin groups versus placebo). Mean changes in FPG from baseline were −10.3, −16.4, and +11.3 mg/dL in the three treatment groups, respectively. As would be expected with DPP-4 inhibitor monotherapy, hypoglycemic events were rare (1.5%--3.0%) during the study, with no hypoglycemic events requiring third-party assistance.

Kutoh and Ukai[@b28-dmso-7-277] conducted a randomized, non-double-blind, non-inferiority trial to evaluate the efficacy and safety of alogliptin versus a low-fat/low-calorie traditional Japanese diet. Enrolled participants were newly diagnosed, drug-naïve Japanese patients with T2DM. Twenty-five participants were randomized to receive 12.5--25.0 mg of alogliptin per day, with 26 participants randomized to receive treatment with a traditional Japanese diet. Participants randomized to the alogliptin arm had a mean A1c of 10.51%, with those allocated to the dietary group having a mean baseline A1c of 10.01%. Following 3 months of treatment, the mean A1c decrease from baseline in the alogliptin group was 1.77%. However, there was no significant difference in A1c reduction between the two groups, with the 95% confidence intervals for A1c change being −2.44% to −1.08% in the alogliptin arm and −2.14% to −1.08% in the diet group. During the 3-month treatment period, four of the 25 participants in the alogliptin group reported mild hypoglycemic events.

Alogliptin as add-on to metformin
---------------------------------

Several clinical trials have investigated the use of alogliptin as add-on to background metformin therapy. Nauck and colleagues[@b20-dmso-7-277] conducted a 26-week, double-blind, randomized, placebo-controlled study in 527 participants with T2DM. For inclusion in the study, participants were required to have a baseline A1c of 7.0%--10.0% and a body mass index of 23--45 kg/m^2^. Enrolled participants had a mean baseline A1c of 7.9%--8.0%, depending on the treatment group. Participants were required to receive a dose of metformin ≥1,500 mg for at least 8 weeks and could not be receiving a medication for the treatment of T2DM other than metformin for the 3 months preceding screening. Participants were randomized to one of three study arms: addition of alogliptin 12.5 mg (n=213), alogliptin 25.0 mg (n=210), or placebo (n=104). For the primary efficacy end point of change in A1c at 26 weeks from baseline, both alogliptin arms achieved an A1c reduction of 0.6%, compared with a reduction of 0.1% in the placebo group (*P*\<0.001 for both comparisons). Additionally, more participants receiving alogliptin achieved an A1c of ≤7.0% when compared with those in the placebo group (*P*\<0.001), and greater reductions in FPG from baseline were seen in the alogliptin 12.5 mg and 25.0 mg groups when compared with placebo (--19, --17, and --0 mg/dL in the three treatment groups, respectively; *P*\<0.001).

Another study of alogliptin as add-on to metformin was conducted in a cohort of Japanese patients with T2DM.[@b21-dmso-7-277] This randomized, double-blind, placebo-controlled study enrolled participants with a baseline A1c of between 6.9% and 10.4% who were receiving a stable dose of metformin for at least 12 weeks prior to screening. Participants underwent an initial 12-week observational period, during which they received 500 mg or 750 mg of metformin daily in addition to lifestyle education. Following the 12-week observational phase, participants (N=288) were randomized to continue metformin therapy in addition to either alogliptin 12.5 mg (n=92), alogliptin 25.0 mg (n=96), or placebo (n=100) for an additional 12-week period (weeks 13--24). Select 12-week efficacy data are summarized in [Table 1](#t1-dmso-7-277){ref-type="table"}. Of note, participants in the metformin plus alogliptin dual-therapy groups exhibited statistically significant improvements in A1c, FPG, and achievement of an A1c ≤7.0% when compared with the metformin plus placebo group. In that study, PPG levels were also assessed, and statistically significant reductions in PPG were demonstrated with alogliptin therapy as add-on to metformin versus placebo. PPG levels were decreased by 33.6 mg/dL in the alogliptin 12.5 mg group, 42.9 mg/dL in the alogliptin 25 mg group, and 3.1 mg/dL in the placebo group. Following the 12-week efficacy phase (weeks 13--24), participants in the placebo group were randomized equally to receive alogliptin 12.5 or 25.0 mg daily in addition to metformin and continue treatment for an additional 40 weeks in an open-label extension period. When analyzing all randomized patients receiving at least one dose of study medication, mean A1c reductions from week 0 to week 52 were 0.44% and 0.58% in the alogliptin 12.5 mg and alogliptin 25.0 mg plus metformin groups, respectively.

Alogliptin plus pioglitazone as initial therapy in drug-naïve patients
----------------------------------------------------------------------

A study involving T2DM patients naïve to T2DM drug therapy was conducted by Rosenstock and colleagues.[@b22-dmso-7-277] The study was performed to assess the efficacy and tolerability of alogliptin in combination with pioglitazone for the initial treatment of drug-naïve patients with inadequate glycemic control (baseline A1c of 7.5%--11%), with the mean baseline A1c ranging from 8.76% to 8.85% in the various treatment groups. This 26-week, double-blind, parallel-group study enrolled 655 participants who were randomized to receive alogliptin 25.0 mg daily (n=164), pioglitazone 30.0 mg daily (n=163), alogliptin 12.5 mg daily plus pioglitazone 30.0 mg daily (n=163), or alogliptin 25.0 mg daily plus pioglitazone 30.0 mg daily (n=164). Mean reductions in A1c from baseline at 26 weeks were −0.96%, −1.15%, −1.56%, and −1.71% in the four groups, respectively. In addition to seeing more A1c reduction in the alogliptin plus pioglitazone groups, a greater percentage of participants receiving combination therapy also achieved an A1c of \<7% at 26 weeks, as noted in [Table 1](#t1-dmso-7-277){ref-type="table"}. Likewise, a statistically significant reduction in FPG was seen in the alogliptin 25 mg daily plus pioglitazone 30 mg daily group when compared with either of the monotherapy groups. When looking at changes in body weight over 26 weeks in the four groups, a statistically significant weight gain was seen in the alogliptin 25 mg daily plus pioglitazone 30 mg daily group when compared with either the alogliptin 25 mg daily or pioglitazone 30 mg daily groups. While the reason for this increase in body weight was not discussed within the research report, it raises the question of additive edema when these agents are used in combination. Given these results, the authors concluded that the combination of alogliptin and pioglitazone appears to be an effective initial treatment option in patients with T2DM.

Alogliptin as add-on to pioglitazone
------------------------------------

A 12-week, randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of alogliptin as add-on to pioglitazone was conducted in Japanese participants with T2DM.[@b23-dmso-7-277] Participants were ≥20 years of age, had an A1c of between 6.9% and 10.4%, and were receiving a stable dose of pioglitazone (15 or 30 mg/day) in addition to diet and exercise for at least 16 weeks. Participants could not have received another antihyperglycemic medication within the previous 16 weeks. Eligible participants were stratified based on pioglitazone dose and randomized to receive the addition of alogliptin 12.5 mg (n=111), alogliptin 25.0 mg (n=113), or placebo (n=115). Mean baseline A1c values in the three study groups ranged from 7.89% to 7.92%. A summary of select efficacy end points can be found in [Table 1](#t1-dmso-7-277){ref-type="table"}. Of note, for the primary end point of change in A1c from baseline to week 12, mean A1c reductions from baseline were 0.91%, 0.97%, and 0.19% in the alogliptin 12.5 mg, alogliptin 25.0 mg, and placebo groups, respectively (*P*\<0.0001 for both alogliptin comparisons versus placebo). Statistically significant improvements were additionally noted with alogliptin add-on to pioglitazone versus placebo for achieving of an A1c \<6.9% and changes from baseline in FPG and PPG.

Alogliptin plus pioglitazone as add-on to metformin
---------------------------------------------------

A study in 1,554 participants with T2DM was conducted to assess the efficacy and tolerability of alogliptin combined with pioglitazone as add-on therapy to metformin.[@b24-dmso-7-277] This 26-week, randomized, double-blind, placebo-controlled study included patients with an A1c of 7.5%--10.0% receiving ≥1,500 mg/day of metformin as monotherapy. Eligible participants were randomized to receive metformin plus placebo, alogliptin (12.5 or 25.0 mg daily) plus metformin, pioglitazone (15, 30 or 45 mg/day) plus metformin, or alogliptin (12.5 or 25.0 mg daily) combined with pioglitazone (15, 30 or 45 mg/day) plus metformin. When assessing the change in A1c from baseline at 26 weeks, the pioglitazone plus metformin pooled group achieved a mean A1c reduction from baseline of 0.9%. In contrast, participants receiving triple therapy (alogliptin, pioglitazone, and metformin) achieved a mean A1c reduction of 1.4% (*P*\<0.001 versus pioglitazone plus metformin pooled group). Of note, groups receiving dual therapy (alogliptin plus metformin or pioglitazone plus metformin) exhibited a higher percentage of patients requiring hyperglycemic rescue (8.5%--14.7%) when compared with any triple-therapy group (1.5%--4.6%). Additional select efficacy data are provided in [Table 1](#t1-dmso-7-277){ref-type="table"}. These findings suggest that the addition of alogliptin and pioglitazone to patients inadequately controlled on metformin monotherapy resulted in an additive reduction in A1c.

Alogliptin as add-on to pioglitazone plus or minus metformin
------------------------------------------------------------

A 52-week study to assess the efficacy and safety of adding alogliptin versus up-titrating pioglitazone in patients with T2DM and inadequate glycemic control (A1c of 7.0%--10.0%) despite metformin plus pioglitazone dual therapy was published by Bosi and colleagues.[@b25-dmso-7-277] Eligible participants were either 1) receiving ≥1,500 mg of metformin (or maximum tolerated dose) plus pioglitazone 30 mg/day for at least 2 months prior to screening or 2) had an A1c of ≥7.5% while receiving metformin plus another oral antidiabetic agent (excluding pioglitazone or a DPP-4 inhibitor) and had a subsequent A1c of between 7.0% and 10.0% after switching to metformin plus pioglitazone 30 mg/day for at least 16 weeks. Study participants were randomized to receive either metformin plus pioglitazone 45 mg/day (n=399) or metformin plus pioglitazone 30 mg/day plus alogliptin 25 mg/day (n=404). Select efficacy data are provided in [Table 1](#t1-dmso-7-277){ref-type="table"}. Of note, participants in the triple-therapy arm had statistically significant reductions from baseline in A1c and FPG when compared with up-titration of pioglitazone, with a numerically greater weight gain in the pioglitazone up-titration group observed.

Alogliptin as add-on to pioglitazone plus or minus metformin and/or sulfonylurea
--------------------------------------------------------------------------------

The efficacy and safety of alogliptin as add-on to pioglitazone plus or minus concomitant metformin or a sulfonylurea was assessed in a double-blind placebo-controlled study.[@b26-dmso-7-277] Participants, aged 18--80, had inadequate glycemic control at the time of enrollment (A1c of 7%--10%). Participants were randomized to receive add-on therapy of alogliptin 12.5 mg (n=197), alogliptin 25.0 mg (n=199), or placebo (n=97) for 26 weeks. Following 26 weeks of treatment, the mean A1c reductions from baseline were −0.66, −0.8 and −0.19% in the alogliptin 12.5 mg, 25.0 mg, and placebo groups, respectively (*P*\<0.001 for both alogliptin groups versus placebo). A significantly larger (*P*≤0.016) proportion of participants in the alogliptin groups achieved an A1c of ≤7% at 26 weeks when compared with the placebo group. FPG reductions from baseline were also greater in the alogliptin groups, with mean reductions of −19.7, −19.9, and −5.7 mg/dL noted in the three treatment groups, respectively.

Alogliptin use in patients with kidney disease
----------------------------------------------

Given the low risk of hypoglycemia and the weight neutrality of the DPP-4 inhibitors, they have gained interest as potentially useful agents in people with T2DM and reduced kidney function. Diabetes itself is a major risk factor for the development of chronic kidney disease,[@b29-dmso-7-277] and several studies have even suggested a renal protective effect with DPP-4 inhibitors.[@b30-dmso-7-277],[@b31-dmso-7-277] Alogliptin is primarily eliminated renally, with exposure increasing incrementally with a decline in renal function.[@b32-dmso-7-277],[@b33-dmso-7-277] Several studies have examined alogliptin use in patients with kidney disease.[@b32-dmso-7-277],[@b33-dmso-7-277] Nakamura and colleagues enrolled 16 participants with T2DM receiving hemodialysis (HD).[@b32-dmso-7-277] Enrolled participants had inadequate glycemic control (defined as an A1c of \>6.5%) from management with diet and exercise alone. No participants were receiving antidiabetic therapy at the time of enrollment. Participants were initiated on alogliptin 6.25 mg once daily. At the conclusion of the study period, mean A1c values decreased from 7.1% at baseline to 5.8% after 24 months of treatment. During the 24-month study, only one serious adverse event (AE) was reported, which was a drug-related rash experienced by one study participant.

Another prospective open-label study was conducted in 30 T2DM participants undergoing HD three times weekly.[@b33-dmso-7-277] Study participants received mitiglinide and/or voglibose during an 8-week observational period, after which they were started on 6.25 mg of alogliptin once daily in addition to their background therapy. Following a 48-week treatment period, mean A1c values decreased from 7.1% at baseline to 6.3% (*P*\<0.0001). Mean PPG levels additionally declined from 212 mg/dL at baseline to 156 mg/dL at week 48 (*P*\<0.0001). No subjects discontinued treatment due to AEs.

While the studies described have been relatively small, they provide support for the efficacy and safety of alogliptin in patients with reduced renal function, including patients with end stage renal disease receiving HD.

Safety and tolerability
=======================

Safety and tolerability data from select Phase III clinical trials and post-marketing reports are discussed in this section. Overall, alogliptin monotherapy is generally well tolerated in most patients, with a generally mild overall side-effect (SE) profile. However, when considering the safety and tolerability of fixed-dose combination products containing alogliptin, safety considerations for both active ingredients must be considered. [Table 2](#t2-dmso-7-277){ref-type="table"} provides select safety and tolerability information from clinical trials included in this review.[@b20-dmso-7-277],[@b21-dmso-7-277],[@b23-dmso-7-277]--[@b26-dmso-7-277] First, safety data from trials with alogliptin in combination with metformin and pioglitazone, respectively, are presented. Second, safety issues of special interest are briefly discussed.

Alogliptin in combination with metformin
----------------------------------------

A review of clinical trials evaluating alogliptin in combination with metformin consistently indicates SE and adverse-drug-event rates that are additive and characteristic of the therapeutic agents when utilized individually.

Nauck et al evaluated alogliptin added to metformin in participants with T2DM inadequately controlled with metformin alone (A1c 7%--10%); patients were randomized to receive placebo (n=104), alogliptin 12.5 mg once daily (n=213), or alogliptin 25.0 mg once daily (n=210), in addition to continued stable daily dosing of at least 1,500 mg of metformin.[@b20-dmso-7-277] The percentage of patients experiencing more than one AE in each group was 66%, 63%, and 57% in the placebo, alogliptin 12.5 mg, and alogliptin 25.0 mg groups, respectively. The percentages of patients with AEs considered drug related were also similar across all groups (10%, 11%, and 13%, respectively), as were the frequencies of serious AEs (4%, 3%, and 4%, respectively). Episodes of hypoglycemia were marginally higher in the metformin plus placebo group (n=3, 3%), with two patients (1%) in the metformin plus alogliptin 12.5 mg group and no patients in the metformin plus alogliptin 25 mg group experiencing a hypoglycemic event. All instances of hypoglycemia were deemed by investigators to be both non-serious and clinically insignificant. Overall, AEs were substantially similar across all three study groups.

Seino et al evaluated alogliptin with metformin in Japanese patients with T2DM for 12 weeks, with a 52-week extension. Patients were randomized to receive metformin with either placebo (n=100), alogliptin 12.5 mg daily (n=92), or alogliptin 25.0 mg daily (n=96).[@b21-dmso-7-277] The most commonly reported AE was nasopharyngitis, with rates of 20.0% in the monotherapy group, 19.6% in the alogliptin 12.5 mg group, and 22.9% in the alogliptin 25.0 mg group reported. Headache, constipation, back pain, eczema, and diarrhea were also common, although no clear trends were evident among the treatment and control groups. A total of six patients receiving alogliptin reported mild skin eruptions, while none were reported in the metformin monotherapy cohort. In the course of the 52-week extension, approximately 78% of patients receiving alogliptin experienced an AE, although only approximately 19% experienced an event judged possibly or probably drug related. No serious drug-related AEs were reported for the 12-week trial, while two serious treatment-related AEs were reported during the 52-week extension. These included infectious enteritis (alogliptin 12.5 plus metformin), and cardiac failure (alogliptin 25.0 mg plus metformin). No patients discontinued the study due to drug-related AEs during the 12-week trial, while three patients discontinued for this reason in the 52-week extension.

Bosi et al evaluated alogliptin as a third agent in T2DM patients with inadequate glycemic control despite treatment with metformin and pioglitazone.[@b25-dmso-7-277] The 52-week parallel-group study observed patients treated with alogliptin 25 mg plus pioglitazone 30 mg plus metformin (≥1,500 mg or stabilized maximally tolerated dose, n=404) versus an up-titration of pioglitazone to 45 mg with stable metformin dosing (n=399). Rates of drug-related AEs were slightly higher in the triple-therapy group (21.8%, n=88) compared with in the metformin plus pioglitazone dual-therapy group (18.8%, n=75), with peripheral edema being the most common (2% and 3%, respectively). The addition of alogliptin also resulted in a higher rate of skin and subcutaneous disorders (5.1% versus \[vs\] 2.3%, respectively), with pruritus and rash being the most common.

Overall, the addition of alogliptin to metformin resulted in additive therapeutic effects without any notable increase in body weight, hypoglycemic events, major cardiac events, or other AEs over metformin monotherapy. Additionally, none of the trials reviewed showed clinically meaningful changes in vital signs, electrocardiograms, serum chemistry, hematology, or urinalysis.[@b20-dmso-7-277],[@b25-dmso-7-277]

Alogliptin in combination with pioglitazone
-------------------------------------------

Pratley et al evaluated alogliptin 12.5 mg, alogliptin 25.0 mg, or placebo with pioglitazone 30 mg or 45 mg once daily in 493 T2DM patients for 26 weeks.[@b26-dmso-7-277] Over 75% of patients were also receiving metformin at a stable dose. During the course of this study, cardiac disorders occurred more frequently in patients receiving alogliptin (6.5% for alogliptin 25.0 mg, 3% for alogliptin 12.5 mg, and 1.0% for placebo). Six patients experienced severe cardiac AEs within the alogliptin treatment arms, and two patients taking alogliptin 25 mg experienced cardiac AEs that were considered possibly drug related (palpations of moderate intensity in one patient and congestive heart failure of moderate intensity in another). Frequencies of drug-related AEs, serious AEs, and discontinuations due to AEs were similar across all groups. Peripheral edema occurred slightly less frequently in the alogliptin 12.5 mg and 25.0 mg cohorts than in the placebo group (6.1%, 5.5%, and 7.2%, respectively). Headache, upper respiratory tract infections, and gastrointestinal AEs occurred with similar frequency between cohorts. Sinusitis and bronchitis occurred slightly less frequently in the alogliptin treatment groups, while AEs involving both infection/infestation and skin/subcutaneous tissue occurred at higher rates in patients receiving alogliptin.

Kaku et al examined alogliptin as add-on to pioglitazone in 339 Japanese participants with T2DM for 12 weeks with a 40-week open-label extension period.[@b23-dmso-7-277] The incidence of AEs was similar for all groups, with 37.8% for pioglitazone plus 12.5 mg alogliptin, 45.1% for pioglitazone plus 25.0 mg alogliptin, and 47.8% for pioglitazone plus placebo. Incidence of drug-related AEs was higher in the alogliptin cohorts, with 7.2%, 8.8%, and 6.1% in the 12.5 mg, 25.0 mg, and placebo groups, respectively. Nasopharyngitis was the most common AE reported, with 4.5% in the 12.5 mg group, 12.4% in the 25.0 mg group, and 5.2% in the placebo group reporting this AE. Edema-related events occurred more frequently in the alogliptin 25.0 mg group than with pioglitazone plus placebo, but no cases were reported within the alogliptin 12.5 mg group. Accordingly, the authors indicated that 12.5 mg may be the optimal alogliptin dose when combined with pioglitazone.

Safety considerations of special interest
-----------------------------------------

### Pancreatitis

Individual cases of pancreatitis in animal and human trials of GLP-1 receptor agonists and DPP-4 inhibitors led to initial concern that these agents may increase the risk of pancreatitis. Some histological studies in animals and tissues derived from organ donors demonstrated β-cell hyperplasia and elevated expression of proliferation markers after exposure to GLP-1 receptor agonists. Because cases of pancreatitis are infrequent, it is difficult to accurately estimate the relative risk. However, post hoc analyses have failed to show an increased risk for diagnosis of, or hospitalization for, pancreatitis in the extensive clinical data available for the GLP-1 agonist exenatide and the DPP-4 inhibitors.[@b15-dmso-7-277],[@b34-dmso-7-277] In the pooled analysis reported in the US prescribing information for alogliptin, pancreatitis was reported in eleven of 5,902 (0.19%) participants receiving alogliptin 25 mg daily versus five of 5,183 (0.096%) of participants receiving placebo or an active comparator in clinical trials.[@b35-dmso-7-277] The EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE) trial, likewise, reported pancreatitis rates for alogliptin similar to placebo in over 7,800 patient-years of observation.[@b36-dmso-7-277] Although the available data do not show any significantly increased incidence or consistent trends in support of a link to pancreatitis with alogliptin or other DPP-4 inhibitors, published prescribing information cautions providers to discontinue alogliptin if pancreatitis is suspected and to initiate therapy with caution in individuals with a history of pancreatitis.[@b35-dmso-7-277]

### Fluid retention and edema

Edema and weight gain are both common AEs associated with pioglitazone.[@b23-dmso-7-277] An increased incidence of edema has been reported when other DPP-4 inhibitors are added to pioglitazone.[@b23-dmso-7-277] Kaku et al and Pratley et al reported no increased incidence of edema-related events in studies of 52-weeks and 26-weeks duration, respectively.[@b23-dmso-7-277],[@b26-dmso-7-277] Kaku and colleagues reported that adding alogliptin to pioglitazone was linked to weight gain and abdominal circumference increases that were small and not clinically significant (weight changes ranging from −0.03 to 0.46 kg).[@b23-dmso-7-277] Another trial reported peripheral edema at a rate of 4% (16 of 404 participants) in a group receiving alogliptin 25 mg with pioglitazone 30 mg and stable metformin dosing, compared with 4.5% (18 of 399 participants) in a group receiving only stable metformin with an up-titration of pioglitazone to 45 mg daily.[@b25-dmso-7-277] Across all studies reviewed, no obvious difference in the incidence of edema-related events was evident with the addition of alogliptin to pioglitazone and/or metformin. That said, the thiazolidinediones are known to contribute to edema and should be used cautiously in individuals at risk for fluid retention.

### Cardiovascular safety

Heart disease, stroke, and other cardiovascular (CV) events occur more frequently in people with T2DM. Long-term CV outcomes and CV-risk-factor modification are thus issues of particular interest for current and future antihyperglycemic therapies. The results of a number of preclinical and clinical studies have led to postulation that DPP-4 inhibitors may actually improve markers of CV disease.[@b37-dmso-7-277] Eliasson et al reported significant reductions in postprandial triglycerides and lipoproteins with alogliptin plus pioglitazone dual therapy.[@b38-dmso-7-277] Long-term alogliptin exposure has also been found to reduce atherosclerosis and inflammation in animal models, via changes in leukocyte chemotaxis and monocyte recruitment.[@b39-dmso-7-277],[@b40-dmso-7-277] In a study of Japanese patients with T2DM, adding alogliptin 25 mg to pioglitazone resulted in statistically significant reductions in total cholesterol (−5.7 mg/dL, SD =21.1) and free fatty acids (−0.04 mg/dL, SD =0.20) relative to pioglitazone alone, with a visible trend toward the reduction of all serum lipid parameters.[@b23-dmso-7-277] While these data are promising, prospective CV outcomes data are required to substantiate such findings with these and other surrogate markers of CV disease.

The EXAMINE trial, initiated in 2011 and completed in 2013, was conducted as a comprehensive evaluation of the safety profile of alogliptin in patients at high risk for CV events. The trial included 5,380 patients with preexisting acute coronary syndrome, randomized to receive either alogliptin or placebo and followed for up to 40 months (median 18 months).[@b36-dmso-7-277] The primary end point was a composite outcome inclusive of CV-related death, nonfatal myocardial infarction, and nonfatal stroke. The primary composite end point occurred in 11.3% of alogliptin recipients and in 11.8% of those receiving placebo (hazard ratio 0.96; *P*\<0.001 for non-inferiority). Secondary end points included all-cause mortality and total CV mortality. No significant differences were seen between groups for the rate of CV mortality (3.3% vs 4.1%), nonfatal myocardial infarction (6.9% vs 6.5%), or nonfatal stroke (1.1% vs 1.2%). Analysis on completion showed no significant differences in any end point or in any individual composite end point, although the alogliptin cohort showed nonsignificant sub-unitary hazard ratios (favoring the addition of alogliptin) in four out of five of the CV event types included in the analysis. Rates of hypoglycemia, cancer, pancreatitis, and initiation of dialysis were also similar between groups. Although the EXAMINE trial demonstrated non-inferiority to placebo in CV safety, the investigators noted that the median treatment duration of 18 months meant that risks or benefits associated with longer-term use could not be ruled out.

Availability and administration
===============================

Alogliptin (Nesina^®^; Takeda Pharmaceutical Company) is available as 6.25, 12.5, and 25.0 mg tablets. The recommended starting dose is 25 mg once daily in people with T2DM. It is recommended that the dose be decreased in patients with renal impairment, with a dose reduction to 12.5 mg once daily in individuals with a creatinine clearance (CrCl) of 30--59 mL/minute, and a further reduction to 6.25 mg once daily with a CrCl of \<30 mL/minute.[@b35-dmso-7-277]

Alogliptin in fixed-dose combination with metformin (Kazano) is available in 12.5/1,000.0 mg and 12.5/500.0 mg tablets.[@b41-dmso-7-277] Twice-daily dosing is recommended to achieve a total daily dose of 25 mg of alogliptin. Because alogliptin and metformin are both eliminated via the kidneys, dosing adjustments are recommended based on CrCl. This product is not recommended to be initiated in patients with a CrCl \<45 mL/minute and is contraindicated with a CrCl \<30 mL/minute, in accordance with current recommendations for metformin use.[@b42-dmso-7-277]

Alogliptin in fixed-dose combination with pioglitazone (Oseni) is commercially available in several combinations: 12.5/15.0 mg, 12.5/30.0 mg, 12.5/45.0 mg, 25.0/15.0 mg, 25.0/30.0 mg, and 25.0/45.0 mg tablets.[@b43-dmso-7-277] The recommended starting dose is 25.0/15.0 mg or 25.0/30.0 mg once daily followed by individualized dose titration based on A1c response and individualized treatment goals. Caution is recommended in patients with heart failure, and recipients should be monitored closely for fluid retention. As with other alogliptin products, Oseni should be titrated according to CrCl to avoid accumulation of the alogliptin component. Of note, alogliptin is the only currently available DPP-4 inhibitor available in fixed-dose combination with pioglitazone.

Discussion
==========

By inhibiting DPP-4, the enzyme responsible for degrading GIP and GLP-1, DPP-4 inhibitors cause a reduction in ambient blood glucose. Clinical trial data with alogliptin demonstrate clinical efficacy in terms of A1c and FPG reductions when used both as monotherapy and in combination with other oral antidiabetic medications.[@b20-dmso-7-277]--[@b28-dmso-7-277] Overall, alogliptin is generally well tolerated when used as monotherapy and in combination with concomitant oral antidiabetic therapies. The most recent clinical practice recommendations from the American Diabetes Association recommend DPP-4 inhibitors as an option for second-line addition to metformin and as a component of three-drug combinations with a variety of antihyperglycemic agents.[@b1-dmso-7-277] Likewise, the 2013 American Association of Clinical Endocrinologists' consensus statement noted DPP-4 inhibitors as having possible benefits when used as monotherapy or as a component of dual or triple therapy.[@b2-dmso-7-277] DPP-4 inhibitors are noted as having a low risk of hypoglycemia, a weight-neutral profile, and favorable tolerability when compared with other pharmacological agents for the treatment of T2DM. DPP-4 inhibitors, such as alogliptin, additionally play a potentially important role in combination therapy due to the benefit of utilizing agents with complementary mechanisms of action.

Alogliptin in combination with metformin provides two distinct mechanisms with the potential for some clinically advantageous overlaps. The glucose-lowering effects of metformin are primarily attributed to modulation of metabolic signaling in the liver and muscle tissues, leading to reduced gluconeogenesis and hepatic glucose output and increased glucose uptake in muscle.[@b44-dmso-7-277],[@b45-dmso-7-277] Metformin has also been shown to significantly increase postprandial GLP-1 levels through mechanisms unrelated to DPP-4 inhibition,[@b45-dmso-7-277] although clinically significant complementary effects were not directly observed in alogliptin/metformin combination studies.[@b46-dmso-7-277] Hence, the pharmacology of alogliptin and metformin may be regarded as independent and complementary. The use of alogliptin in combination with pioglitazone is likewise rational if seeking agents with complementary mechanisms of action. Pioglitazone stimulates the peroxisome proliferator-activated receptor gamma, signaling changes in gene transcription that ultimately result in enhanced insulin response in hepatic, adipose, and skeletal muscle tissues.[@b47-dmso-7-277] Of note, alogliptin is the only DPP-4 inhibitor currently available commercially in fixed-dose combination with a thiazolidinedione.

In terms of safety, DPP-4 inhibitors are generally well tolerated and demonstrate similar SE profiles in clinical trials. As highlighted in [Table 2](#t2-dmso-7-277){ref-type="table"}, alogliptin in combination with metformin and pioglitazone was generally well tolerated in the clinical trial setting. One critical advantage of such combinations is the low risk of hypoglycemia -- perhaps of significant clinical importance in the elderly. A pooled analysis of data pertaining to alogliptin use in patients ages 65 to 80 was conducted by Pratley et al in 2009.[@b48-dmso-7-277] Alogliptin was generally found to be safe and well tolerated in elderly patients, and no meaningful differences were apparent in the overall rates of AEs compared with patients aged 18--64. A higher percentage of elderly patients experienced a serious AE; however, this trend was evident in both the placebo and alogliptin groups and may be due only to the differences in age. No difference in weight gain was observed across treatment groups or between age groups. In elderly patients, the highest incidences of hypoglycemia of all severity levels were reported for the placebo group. The study authors noted that severe hypoglycemia is associated with increased mortality in elderly patients, so an opportunity to enhance glycemic control without increasing this treatment-limiting risk is an appealing possibility.[@b48-dmso-7-277] Of additional importance in elderly individuals, dose titration based on renal function is necessary with alogliptin. Assessment of renal function and appropriate dose titration is additionally warranted with metformin for those individuals receiving alogliptin plus metformin combination therapy.

However, additional safety concerns have recently arisen regarding a potential link between DPP-4 inhibitor use and the occurrence of pancreatitis. While there is some debate regarding whether the reported cases of pancreatitis are in fact attributable to DPP-4 inhibitor use, the US Food and Drug Administration recommends that patients be monitored carefully for the development of pancreatitis during the initiation and upward titration of these agents.

Conclusion
==========

Clinical efficacy data support the use of alogliptin in combination with metformin and pioglitazone in the treatment of T2DM. Due to the progressive nature of T2DM, multiple agents addressing different, yet complementary, mechanisms of action are frequently needed to achieve individualized glycemic goals. Given the multitude of medications often taken by individuals with T2DM, fixed-dose products provide an option for practitioners to decrease the pill burden placed on patients. Alogliptin in fixed-dose combination with metformin (Kazano) and pioglitazone (Oseni) offer a welcome option for patients and providers wishing to simplify complex medication regimens.
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###### 

Select efficacy outcomes from alogliptin clinical trials

  Study                               Pts (n)   Treatment                                                                                    Treatment Period (weeks)                                                                    A1c change (%)                                                                               Achievement of A1c ≤7% (%)                                                                  FPG change (mg/dL)                             BW change (kg)   
  ----------------------------------- --------- -------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------- ---------------------------------------------- ---------------- -------
  Nauck et al[@b20-dmso-7-277]        527       MET ≥1,500 mg                                                                                PBO                                                                                         26                                                                                           −0.1                                                                                        18                                             0                --
  ALO 12.5                                      −0.6[a](#tfn1-dmso-7-277){ref-type="table-fn"}                                               52[a](#tfn1-dmso-7-277){ref-type="table-fn"}                                                −19[a](#tfn1-dmso-7-277){ref-type="table-fn"}                                                0.0[b](#tfn2-dmso-7-277){ref-type="table-fn"}                                                                                                               
  ALO 25                                        −0.6[a](#tfn1-dmso-7-277){ref-type="table-fn"}                                               44[a](#tfn1-dmso-7-277){ref-type="table-fn"}                                                −17[a](#tfn1-dmso-7-277){ref-type="table-fn"}                                                −0.3[b](#tfn2-dmso-7-277){ref-type="table-fn"}                                                                                                              
  Seino et al[@b21-dmso-7-277]        288       MET 500 or 750 mg                                                                            PBO                                                                                         12                                                                                           0.21                                                                                        2.0                                            −0.80            −0.23
  ALO 12.5                                      −0.54[a](#tfn1-dmso-7-277){ref-type="table-fn"}                                              28.3[c](#tfn3-dmso-7-277){ref-type="table-fn"}                                              −19.0[a](#tfn1-dmso-7-277){ref-type="table-fn"}                                              0.17[c](#tfn3-dmso-7-277){ref-type="table-fn"}                                                                                                              
  ALO 25                                        −0.64[a](#tfn1-dmso-7-277){ref-type="table-fn"}                                              27.1[c](#tfn3-dmso-7-277){ref-type="table-fn"}                                              −23.1[a](#tfn1-dmso-7-277){ref-type="table-fn"}                                              −0.09                                                                                                                                                       
  Rosenstock et al[@b22-dmso-7-277]   655       Drug naïve                                                                                   ALO 25                                                                                      26                                                                                           −0.96                                                                                       24.4                                           −25.2            −0.29
  PIO 30                                        −1.15                                                                                        33.7                                                                                        −37.8                                                                                        2.19                                                                                                                                                        
  ALO 12.5 + PIO 30                             −1.56[d](#tfn4-dmso-7-277){ref-type="table-fn"}                                              53.4[d](#tfn4-dmso-7-277){ref-type="table-fn"}                                              −48.6[d](#tfn4-dmso-7-277){ref-type="table-fn"}                                              2.51                                                                                                                                                        
  ALO 25 + PIO 30                               −1.71[d](#tfn4-dmso-7-277){ref-type="table-fn"},[e](#tfn5-dmso-7-277){ref-type="table-fn"}   62.8[d](#tfn4-dmso-7-277){ref-type="table-fn"},[e](#tfn5-dmso-7-277){ref-type="table-fn"}   −50.5[d](#tfn4-dmso-7-277){ref-type="table-fn"},[e](#tfn5-dmso-7-277){ref-type="table-fn"}   3.14[d](#tfn4-dmso-7-277){ref-type="table-fn"},[e](#tfn5-dmso-7-277){ref-type="table-fn"}                                                                   
  Kaku et al[@b23-dmso-7-277]         339       PIO 15--30 mg                                                                                PBO                                                                                         12                                                                                           −0.19                                                                                       20[g](#tfn7-dmso-7-277){ref-type="table-fn"}   −2.4             −0.03
  ALO 12.5                                      −0.91[f](#tfn6-dmso-7-277){ref-type="table-fn"}                                              49.5[f](#tfn6-dmso-7-277){ref-type="table-fn"},[g](#tfn7-dmso-7-277){ref-type="table-fn"}   −14.9[f](#tfn6-dmso-7-277){ref-type="table-fn"}                                              0.48[f](#tfn6-dmso-7-277){ref-type="table-fn"}                                                                                                              
  ALO 25                                        −0.97[f](#tfn6-dmso-7-277){ref-type="table-fn"}                                              49.6[f](#tfn6-dmso-7-277){ref-type="table-fn"},[g](#tfn7-dmso-7-277){ref-type="table-fn"}   −18.9[f](#tfn6-dmso-7-277){ref-type="table-fn"}                                              0.46[f](#tfn6-dmso-7-277){ref-type="table-fn"}                                                                                                              
  DeFronzo et al[@b24-dmso-7-277]     1,554     MET ≥1,500 mg                                                                                PIO 15--45                                                                                  26                                                                                           −0.9                                                                                        30.5                                           −28.8            1.5
  PIO 15--45 + ALO 12.5                         −1.4[h](#tfn8-dmso-7-277){ref-type="table-fn"}                                               54.6[h](#tfn8-dmso-7-277){ref-type="table-fn"}                                              −45.0[h](#tfn8-dmso-7-277){ref-type="table-fn"}                                              1.8                                                                                                                                                         
  PIO 15--45 + ALO 25                           −1.4[h](#tfn8-dmso-7-277){ref-type="table-fn"}                                               55.9[h](#tfn8-dmso-7-277){ref-type="table-fn"}                                              −45.0[h](#tfn8-dmso-7-277){ref-type="table-fn"}                                              1.9                                                                                                                                                         
  Bosi et al[@b25-dmso-7-277]         803       MET ≥1,500 mg or MTD                                                                         PIO 45                                                                                      52                                                                                           −0.29                                                                                       21.3                                           −3.6             1.6
  PIO 30 + ALO 25                               −0.70[h](#tfn8-dmso-7-277){ref-type="table-fn"}                                              33.2[h](#tfn8-dmso-7-277){ref-type="table-fn"}                                              −14.4[h](#tfn8-dmso-7-277){ref-type="table-fn"}                                              1.1                                                                                                                                                         
  Pratley et al[@b26-dmso-7-277]      493       PIO ± MET/SU                                                                                 PBO                                                                                         26                                                                                           −0.19                                                                                       34.0                                           −5.7             --
  ALO 12.5                                      −0.66[a](#tfn1-dmso-7-277){ref-type="table-fn"}                                              44.2[i](#tfn9-dmso-7-277){ref-type="table-fn"}                                              −19.7[j](#tfn10-dmso-7-277){ref-type="table-fn"}                                             0.42[b](#tfn2-dmso-7-277){ref-type="table-fn"}                                                                                                              
  ALO 25                                        −0.80[a](#tfn1-dmso-7-277){ref-type="table-fn"}                                              49.2[i](#tfn9-dmso-7-277){ref-type="table-fn"}                                              −19.9[j](#tfn10-dmso-7-277){ref-type="table-fn"}                                             0.05[b](#tfn2-dmso-7-277){ref-type="table-fn"}                                                                                                              

**Notes:**

*P*\<0.001 versus placebo

least-squares mean difference relative to placebo

statistically significant versus change with MET monotherapy

*P*\<0.05 versus PIO 30

*P*\<0.05 versus ALO 25

*P*\<0.05 versus PBO

Goal A1c threshold of \<6.9%

*P*\<0.001 versus PIO alone

*P*≤0.016 versus placebo

*P*\<0.003 versus placebo.

**Abbreviations:** A1c, glycosylated hemoglobin; ALO, alogliptin; BW, body weight; FPG, fasting plasma glucose; MET, metformin; MTD, maximum tolerated dose; PBO, placebo; PIO, pioglitazone; PPG, postprandial glucose; Pts, participants randomized; SU, sulfonylurea.

###### 

Select adverse-drug-event rates from selected alogliptin clinical trials

  Study                             Treatment group (intervention, mg)   Discontinuation due to AE (n \[%\])   Diarrhea (n \[%\])   Nasopharyngitis (n \[%\])   Arthralgia (n \[%\])   Headache (n \[%\])   Severe hypoglycemia (n \[%\])   Peripheral edema (n \[%\])
  --------------------------------- ------------------------------------ ------------------------------------- -------------------- --------------------------- ---------------------- -------------------- ------------------------------- ----------------------------
  Nauck et al[@b20-dmso-7-277]      MET + PBO                            1 (1)                                 6 (6)                6 (6)                       5 (5)                  2 (2)                0 (0)                           NR
  MET + ALO 12.5                    7 (3)                                6 (3)                                 12 (6)               4 (2)                       8 (4)                  0 (0)                NR                              
  MET + ALO 25                      4 (2)                                7 (3)                                 7 (3)                3 (1)                       4 (2)                  0 (0)                NR                              
  Seino et al[@b21-dmso-7-277]      MET + PBO                            0 (0)                                 1 (1)                20 (20.0)                   0 (0)                  0 (0)                0 (0)                           NR
  MET + ALO 12.5                    0 (0)                                5 (5.4)                               18 (19.6)            0 (0)                       6 (6.5)                0 (0)                NR                              
  MET + ALO 25                      0 (0)                                1 (1)                                 22 (22.9)            1 (1)                       0 (0)                  0 (0)                NR                              
  Kaku et al[@b23-dmso-7-277]       PIO + PBO                            4 (3.5)                               NR                   6 (5.2)                     NR                     NR                   0 (0)                           2 (1.7)
  PIO + ALO 12.5                    1 (0.9)                              NR                                    5 (4.5)              2 (1.8)                     NR                     0 (0)                0 (0)                           
  PIO + ALO 25                      2 (1.8)                              NR                                    (12.4)               (9.1)                       NR                     0 (0)                (2.7)                           
  DeFronzo et al[@b24-dmso-7-277]   MET + PIO + PBO                      11 (2.8)                              14 (3.6)             11 (2.8)                    13 (3.4)               23 (5.9)             2 (0.5)                         10 (2.6)
  MET + PIO + ALO 12.5              8 (2.1)                              9 (2.3)                               19 (4.9)             11 (2.8)                    13 (3.3)               0 (0)                10 (2.6)                        
  MET + PIO + ALO 25                6 (1.5)                              20 (5.1)                              21 (5.4)             12 (3.1)                    14 (3.6)               1 (0.3)              14 (3.6)                        
  Bosi et al[@b25-dmso-7-277]       MET + PIO 30 + ALO 25                12 (3.0)                              11 (2.7)             28 (6.9)                    13 (3.2)               19 (4.7)             2 (0.5)                         16 (4.0)
  MET + PIO 45                      16 (4.0)                             24 (6.0)                              21 (5.3)             13 (3.3)                    16 (4.0)               0 (0)                18 (4.5)                        
  Pratley et al[@b26-dmso-7-277]    PIO + PBO ± MET/SU                   3 (3.1)                               NR                   6 (6.2)                     NR                     4 (4.1)              NR                              7 (7.2)
  PIO + ALO 12.5 ± MET/SU           6 (3.0)                              NR                                    8 (4.0)              NR                          8 (4.0)                NR                   12 (6.1)                        
  PIO + ALO 25 ± MET/SU             6 (3.0)                              NR                                    14 (7.0)             NR                          10 (5.0)               NR                   11 (5.5)                        

**Abbreviations:** AE, adverse event; ALO, alogliptin; MET, metformin; NR, not reported; PBO, placebo; PIO, pioglitazone; SU, sulfonylurea.
